Member Info for RayPointer

Hi Inan

Great posts.

Do we know if the Antibody part of the vaccine will be making use of Avidimab?

I haven't seen it mentioned anywhere but I may just have missed it.

Yes, this is the same article that cc posted.
The case for a vaccine that activates TCells is growing.
Scancell should definitely try to capitalise on this.

Now that's a good find cc.
The 3rd article that indicates how important TCells are in this fight.

I agree with Moljen. A simple powerful message needs to be emphasised.

Something like
"Covidity's aim is to give a powerful boost to the Immune system",
"We are convinced this is the best way to defeat the virus",
"The science has already been proven in a much harsher environment, that of cancer",
"The project is headed by a world renowned scientist"

Every sentence should be positive.

Steer clear of words like "maybe", "hopefully", "perhaps". Adverts don't use these words and, in the limited air time we get, CH or whoever should think in advertising terms.
I bet the CEO of Moderna is good at this.

You make some good points Chester.

Regrettably, PR has never been Scancell's forte. The same could be said of their ability to keep their investors informed.
I do think that CH, when given the chance, should go to town more on the virtues of Immunobody. I think that's what Lindy would be doing if she were being interviewed.

On the question of funding, perhaps potential investors are waiting until the project is a little more advanced and it is clearer that this is a serious contender.

ATB

Immunobody employs both direct and cross presentation

https://www.scancell.co.uk/immunobody

"As a result of both the direct and cross-presentation, the T cells not only have a higher avidity (up to 100-fold increased potency), but there are many more T cells generated against the epitopes of interest."

Whereas versamune only appears to use cross presentation

https://www.pdsbiotech.com/versamune-platform/

"Versamune® has been demonstrated to induce neutralizing antibodies in response to the protein and promote cross-presentation of the antigen to both CD4+ helper and CD8+ killer T-cells."

No mention of direct presentation

He is also a Professor at Nottingham Uni

https://www.nottingham.ac.uk/news/pressreleases/2017/september/professor-jonathan-van-tam-to-be-deputy-chief-medical-officer-for-england.aspx

a Nottingham Uni graduate, rather than the normal Oxford graduate

https://www.telegraph.co.uk/global-health/science-and-disease/covid-19-coronavirus-vaccine-trials-latest-uk/

"On April 17, the government launched a taskforce designed to "rapidly develop a coronavirus vaccine", as well as scale up manufacturing so it can be quickly produced and delivered in mass quantities.

It will be led by Sir Patrick Vallance and Professor Jonathan van Tam, the deputy chief medical officer, and members will include AstraZeneca and the Wellcome Trust."

Professor Jonathan van Tam

https://en.wikipedia.org/wiki/Jonathan_Van-Tam

"He graduated in Medicine from the University of Nottingham in 1987."

Surely he has heard of Lindy

What we need is a re-vamped version of this famous poster
https://www.bbc.co.uk/news/magazine-28642846

But seriously, Scancell should be trying to match the publicity that the Oxford Uni vaccine is attracting.
Even Donald Trump knows about this vaccine.
Perhaps someone should tell him that Covidity is based on disinfectant.

On the question of funding, I wonder what proportion of Scancell's resources are working on the Covidity project.
I would suggest that maybe only those concerned with Modi1 manufacture and on-going Moditope research are working on cancer related projects.
So perhaps, if and when Covid19 funding is agreed, this will pay most of Scancell's bills.
A cash raise would presumably still be necessary to keep the cancer side of things going at some point, but hopefully the order of events is
a) secure Covidity funding
b) resultant increased SP (hopefully sustained)
c) cash raise for the cancer side of things at a much higher price than previously thought likely

Then we also have the on-going 4 collaborations to perhaps also bring in some much needed cash in the not too distant future

Thanks LL

I haven't listened yet to the youtube, but I did notice one of the comments

"Could WHO make a video explaining the many different strains of Covid 19 that are circulating the World & in what ways each strain differs from one another. For example the different strain in the state of Washington USA seems to be much less deadly & less contagious than the virus strain in New York USA. The virus strain that has hit European countries like Italy, U.K. & Spain appears to be especially contagious & deadly like the strain in New York. Germany has had a different less virulent strain of the virus. Viruses always mutate. Please WHO give us the information about the mutations Covid 19 has already gone through & let us know if “second waves” of infection could actually be a first wave of a different strain of Covid 19"

Do the different mutations of the virus present different targets on the spike proteins?
It would be interesting to know if Lindy's TCell approach would provide the flexibility to quickly re-engineer the vaccine to attack different targets.

It can be confusing because some TCells act more like innate immune system cells, but are still part of the adaptive immune system.

https://en.wikipedia.org/wiki/T_cell

See the section on innate like T Cells

https://en.wikipedia.org/wiki/T_cell#Innate-like_T_cells

As an aside, CD4 cytotoxic TCells do not even get a mention. Perhaps their significance is only just beginning to be understood.

The SP seems to be up and down like a yoyo today.
Come on Cliff, get that funding sorted out.

Now we just need to figure out how to make comments without having a subscription.
Love, the hacker twins

If you google "How to pick a real winner in the Covid-19 vaccine race" it gets you round the pay wall.

"If ImmunoBody works on cancer and Covid what else does it work on."

Well I think the answer to that is any treatment for any disease that would benefit from a targeted TCell attack.
I would say that the Dendritic cells function in the same way no matter what the TCell target is.
As long as the target is in the human repertoire of TCells, the Dendritic cell will activate the TCell, give it high avidity and program it for clonal expansion. All IMO.

A slightly different smile, but its still there.

https://www.youtube.com/watch?v=iaWlhdesc9I

Lindy is at the starting traps but her jockey has not arrived yet.
If the jockey arrives will she run a good race.

Ask the bookies!

I still think that the Scancell approach looks to be the most interesting. Has anyone seen mention of another approach that uses both Antibodies and TCells to neutralise the virus?

The fact that studies are beginning to indicate that people who have recovered have long lasting memory TCells but only weak antibody protection is IMO significant.

Here's an article about the SARS coronavirus

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362397/

and a more recent article about covid19

https://www.bbc.com/future/article/20200421-will-we-ever-be-immune-to-covid-19

"“Antibodies are not the only answer,” says Iwasaki. “We don’t know why the people recovered but I suspect it was because they had a very good T cell response.”
The sample size in this study was small, so whether that ratio of convalescent patients with and without antibodies scales up to the larger population remains to be seen."

Back to Immunobody. This has probably been posted a number of times but it is well worth a read for those new to Scancell

https://www.scancell.co.uk/immunobody

" As a result of both the direct and cross-presentation, the T cells not only have a higher avidity (up to 100-fold increased potency), but there are many more T cells generated against the epitopes of interest."

And from the article that Wild posted

"“Vaccines are the long-term solution and we believe our combined high avidity T cell and neutralizing antibody approach has the potential to produce a second-generation vaccine that will generate an effective and durable immune response to COVID-19,” said Professor Lindy Durrant, Chief Scientific Officer Scancell."

I managed to put 2 comments against the article.
It appears that it takes about 10 minutes after posting for the comment to become visible

Hi Inan

Could you explain how immune response can be measured in humans for different delivery methods without a clinical trial?

Thanks